GlobeNewswire by notified

New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic

Share

COPENHAGEN, Denmark, December 8, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to issue warrants to members of the Executive Management and selected employees in the Bavarian Nordic Group. As a new initiative, vesting of the warrants for members of the Executive Management will be based on successful achievement of relevant Key Performance Indicators (KPI's). The decision is made in accordance with the shareholder authorizations for the Board of Directors adopted as Articles 5b and 5c of the Articles of Association and the Remuneration Policy.

A total of 248,787 warrants is granted to members of Executive Management with a subscription price of DKK 224.70 per share equivalent to the market price of Bavarian Nordic's shares at the time of grant. Vesting of the warrants is subject to prior fulfilment of KPI's as determined by the Board of Directors.

A total of 683,264 warrants is granted to selected employees in the Bavarian Nordic Group with a subscription price of DKK 270.91 per share, determined as the average market price (closing price) of the Company's shares on Nasdaq Copenhagen over a period of 15 business days prior to grant plus 15 %.

Collectively, under the new warrant programs a total of 932,051 warrants are granted, which entitle the holders to subscribe for up to 932,051 shares in total with a nominal value of DKK 10 each. Vested warrants may be exercised wholly or partly during eight fixed subscription periods during 2026 and 2027, however subject to predefined caps on the maximum value of the exercise for each individual warrant holder at the time of exercise as laid out in the Remuneration Policy.

Calculated on the Black-Scholes model, the theoretical value of each warrant granted to members of Executive Management equals DKK 78.36 and the value of each warrant granted to selected employees equals DKK 64.33. The calculations are based on a share price of DKK 224.70, a risk-free interest rate of 2.04 per cent and on the historical volatility of the shares in relevant peers. The value of warrants granted to members of Executive Management will further be adjusted for the historic probability of achievement of KPIs.

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against mpox (monkeypox). The vaccine is also approved in Canada and Europe. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Company Announcement no. 43 / 2022

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Graid Technology Announces Software Update Targeted at Enhancing Business Continuity for NVMe Deployments2.2.2023 15:00:00 CET | Press release

SupremeRAID™ new high availability feature provides an additional level of business continuity protection coupled with superior overall performance. SANTA CLARA, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Graid Technology, the award-winning data protection provider and developer of the only RAID card to offer customers access to the full performance of NVMe SSDs, is proud to announce its latest software release (V1.3) for SupremeRAID™ SR-1000 and SR-1010. The various enhancements in this release include features and software updates designed to support dual controller high availability along with support for multiple new NVMe SSDs. Among the enhanced features in the new release is a configurable strip size, allowing customers using RAID 0 and RAID 10 to realize even better server performance, a strategic move that continues to position SupremeRAID™ as the performance leader for both random and sequential workloads. "This latest release gives our customers peace of mind knowing that thei

Global Chauffeur Service Blacklane names Cindy Rubbens as Chief People Experience Officer and Gudrun Herrmann as Global Head of Communications2.2.2023 14:45:44 CET | Press release

Rubbens will oversee the continuous scaling of Blacklane while driving growth via learning and development, while Herrmann is tasked with building up an external and internal strategic communications function and co-drive its sustainability efforts. BERLIN, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Global chauffeur service, Blacklane, announced that it has named Cindy Rubbens Chief People Experience Officer (CPXO) and Gudrun Herrmann Global Head of Communications, effective immediately. Both will report to Blacklane CEO and CO-Founder Dr. Jens Wohltorf and will be charged with developing the Talent Attraction and Human Resources as well as Communications respectively during the company’s bid to scale while driving the next phase of growth. In her role as CPXO, Rubbens will support the sustainable development of Blacklane’s crew while the business continues scaling new, industry-leading services and expanding markets. Rubbens will focus on strengthening the Talent Attraction function while assi

Landsbankinn hf.: Financial results of Landsbankinn for 20222.2.2023 14:36:13 CET | Press release

Landsbankinn's net profit in 2022 was ISK 17.0 billion. There was good growth in loans to corporates, ISK 92.0 billion or the equivalent of 10%, having regard for currency changes.Mortgage loans grew by 59.0 billion with demand decreasing in the fourth quarter.ROE in the fourth quarter of 2022 was 8.2%, compared with 10.5% ROE in the same quarter of 2021. ROE in 2022 was 6.3%, despite solid core earnings. The negative impact reducing profitability was mainly a decrease in the fair value of the Bank’s holding in Eyrir Invest hf. The Bank’s target ROE is 10% at a minimum. Operating expenses are stable. Landsbankinn topped the Icelandic Performance Satisfaction Index for banking customers the fourth year in a row. The Bank’s market share in the retail market has never been higher and measures over 40% for the first time. Loans in arrears are at a historic low and loans in arrears were 0.2% at the turn of the year.In 2022, the Bank paid a dividend of ISK 20.5 billion and ISK 14.1 billion i

Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference2.2.2023 14:00:00 CET | Press release

BOSTON and LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that members of its management team will participate in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 8:00 a.m. ET. A webcast of the fireside chat, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations. About Centessa Pharmaceuticals Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications. We operate with the conviction that

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa2.2.2023 14:00:00 CET | Press release

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody®sonelokimab in moderate-to-severe hidradenitis suppurativa Enrollment target of 210 patients randomized completed ahead of scheduleTop line results on the primary endpoint, for the novel IL-17A and IL-17F inhibitor Nanobody® sonelokimab, expected mid-2023First registered randomized trial in HS to use HiSCR75 as the primary endpoint; trial also includes adalimumab as an active reference armThe trial will proceed to its 24-week completion, including placebo patients re-randomized to sonelokimab and adalimumab patients switched to sonelokimab, with final read out expected, as planned, by Q4 2023 ZUG, Switzerland, February 2, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has completed enrollment of the target 210 pa